A controversial new drug has been developed that significantly reduces the symptoms of a rare genetic disease. However, the pharmaceutical company charges £100,000 per year for treatment, which the National Health Service considers too expensive. The company argues that the high price is justified because they need to recoup the billions spent on research and development. Patient advocates respond that while the company deserves to recover its costs and make reasonable profit, no price can be justified if it means that sick people who could be helped are instead left to suffer. The right to health must take precedence over the right to unlimited profit.